The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more medication.
Zacks Investment Research on MSN19d
J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy UseJohnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for Spravato (esketamine) as a monotherapy for adults living with ...
Inquirer on MSN6d
World’s first anti-depression nasal spray receives FDA approvalThe US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...
The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...
The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...
The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a ...
The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback